Thank you for attending CPhI Japan 2022 (International Pharmaceutical Development Exhibition)!
Sperafarma exhibited at CPhI Japan 2022 (International Pharmaceutical Development Exhibition, April 20-22, Tokyo Big Sight) and welcomed many customers to our booth. As a CDMO capable of providing a wide range of services from early-stage R&D to the manufacturing of clinical trial drugs, commercial manufacturing, and raw material procurement, we will accelerate our support for pharmaceutical development. We would like to express our gratitude to everyone who provided us with opportunities for exchanging opinions and sharing information. 【Overview of Presentations at the Booth】 ■ Screening technologies required in active pharmaceutical ingredient research - catalyst selection, crystallization - ■ Mutagenic impurities in pharmaceuticals (active pharmaceutical ingredients) - development of testing methods and analysis examples - *For more details, please refer to the PDF materials or feel free to contact us.
Inquire About This Product
basic information
For more details, please refer to the PDF document or feel free to contact us.
Price range
Delivery Time
Applications/Examples of results
For more details, please refer to the PDF document or feel free to contact us.
catalog（1）
Download All Catalogs
Company information
Our company is a pharmaceutical CMC research and development contract company that spun out from the CMC research division of Takeda Pharmaceutical Company Limited in July 2017. We support excellent pharmaceutical development as experts in CMC research. Our research team consists of experts with extensive experience and achievements in process chemistry, formulation research and development, and analytical testing development related to CMC research. We provide high-level services and solutions tailored to our customers' needs across each process from the early stages of pharmaceutical development to application, while flexibly collaborating. We have established a collaborative system with partner companies, enabling us to offer a one-stop service. Please utilize us as a platform for your pharmaceutical development.